New hope for penile cancer: drug targets tumors by blocking key protein
NCT ID NCT03391479
First seen Jan 04, 2026 · Last updated May 06, 2026 · Updated 27 times
Summary
This phase 2 trial tests the drug avelumab in 25 people with advanced penile cancer who cannot have standard platinum chemo or whose cancer worsened after it. Avelumab works by blocking a protein called PD-L1, which may help shrink or stop tumor growth. The main goal is to see how many patients' tumors respond to the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.